In an updated dataset of 24 patients with recurrent WHO grade III/IV IDH1‑mutant astrocytoma treated with intranasal NEO100, radiographic responses were observed in 21% of patients, six-month progression-free survival reached 44%, and 33% remained alive at or beyond 18 months. Responses were confirmed on contrast-enhanced and perfusion MRI, and no significant toxicity was reported with chronic intranasal administration.
The announcement reflects pooled results from an ongoing Phase 1/2a program and compassionate-use experience, assessed under RANO criteria and benchmarked against historical outcomes for salvage therapy in recurrent high-grade glioma, where response rates are typically under 8% and PFS-6 ranges from 21% to 31%. The agent is delivered intranasally, aiming to address drug delivery constraints imposed by the blood–brain barrier in CNS malignancies. Enrollment in the Phase 2a cohort is approaching completion, with a fuller readout expected six months post-enrollment.
Strategically, NeOnc is positioning NEO100 as a CNS-penetrant metabolic therapy for a biomarker-defined subset within a notoriously treatment-resistant setting. The intranasal route is the differentiation between—if the efficacy and tolerability signals hold, it could support a home-based regimen that reduces infusion burden and site chair time. The tension is that the current readout is small, single-arm, and combines data across study phases and a compassionate-use case, which limits interpretability and elevates the risk of selection and survivorship bias. The IDH1-mutant population can have a more indolent course than IDH1 wild-type high-grade glioma, complicating comparisons to historical controls. Imaging-defined responses and PFS-6 are favorable signals, but regulators will expect consistency on overall survival and durability beyond steroid effects or imaging variability.
For sites, the operational footprint is non-trivial despite the appeal of at-home dosing. Perfusion MRI confirmation and adherence to standardized RANO-based imaging protocols point to the need for core-lab partnerships, harmonized MRI acquisition, and tight visit scheduling to reduce measurement noise. Training patients in correct intranasal administration, documenting use, and monitoring local tolerability become core workflows, which advantage sites with robust remote monitoring and pharmacy support. CROs and sponsors should anticipate device logistics, home services integration, ePRO for dose capture, and central imaging review as table stakes in later-phase design. Regulators are likely to push for a randomized control against accepted salvage comparators, stratified by grade, prior therapies, and key covariates, with pre-specified OS and durable response endpoints. Vendors in imaging, DCT enablement, and adherence analytics stand to benefit if the program advances.
The next signal to watch is the complete Phase 2a dataset with mature PFS and OS curves, central reads, and subgroup cuts that separate grade III from IV disease and account for prior bevacizumab or alkylator exposure. Clarity on steroid use, quality-of-life measures, and steroid-sparing effects will matter as the FDA weighs the clinical meaningfulness of radiographic response in glioma. A randomized Phase 2/3 protocol—potentially against lomustine-based salvage or bevacizumab-containing regimens in the IDH1‑mutant segment—will reveal the company’s regulatory ambition and operational readiness, including drug-device classification, CMC for chronic nasal dosing, and scaling of training and monitoring. The risk remains that single-arm gains relative to historical benchmarks may not translate under randomization; the opportunity is a tolerable, CNS-directed option that could shift trial execution toward hybrid models pairing home dosing with rigorous, centralized imaging oversight.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
